Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Compulsive personality disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Compulsive personality disorder. Displaying page 1 of 1.
    EudraCT Number: 2011-002819-28 Sponsor Protocol Number: OCDDCS001 Start Date*: 2012-04-12
    Sponsor Name:Stockholms Läns Landsting
    Full Title: Internet-based cognitive behavior therapy in combination with D-Cycloserine for Obsessive Compulsive Disorder: A double blinded randomized controlled trial
    Medical condition: Obsessive Compulsive disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10029898 Obsessive-compulsive disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016713-20 Sponsor Protocol Number: CL2-20098-072 Start Date*: 2010-04-13
    Sponsor Name:Laboratorios Servier S.L.
    Full Title: Eficacia de agomelatina 25mg/día (con posibilidad de incremento a 50mg/día tras 8 semanas de tratamiento) por vía oral durante 16 semanas en pacientes con Trastorno Obsesivo Compulsivo // Efficacy...
    Medical condition: Trastorno Obsesivo Compulsivo // Obsessive-compulsive disorder
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029898 Obsessive-compulsive disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000367-18 Sponsor Protocol Number: 200702 Start Date*: 2007-07-12
    Sponsor Name:Meerkanten GGz
    Full Title: The effect of the addition of D-cycloserine to exposure sessions in the treatment of patients with obsessive-compulsive disorder. A randomized, placebo-controlled trial.
    Medical condition: Obsessive-Compulsive Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029898 Obsessive-compulsive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016751-22 Sponsor Protocol Number: ABR30311 Start Date*: 2010-04-01
    Sponsor Name:AMC, divisie Psychiatrie
    Full Title: A double blind, placebo controlled study of memantine in patients with obsessive-compulsive disorder.
    Medical condition: Obsessive-compulsive disorder (OCD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10030029 OCD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006947-38 Sponsor Protocol Number: RAA2008-014 Start Date*: 2009-01-15
    Sponsor Name:King's College London (Institute of Pyschiatry)
    Full Title: A randomised double-blind placebo-controlled pilot study of D-cycloserine-augmented exposure therapy in adolescents with obsessive-compulsive disorder
    Medical condition: Obsessive-compulsive disorder (OCD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029898 Obsessive-compulsive disorder LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016443-19 Sponsor Protocol Number: PPG-TOC2009 Start Date*: 2010-01-26
    Sponsor Name:CHU de Poitiers
    Full Title: Etude prospective du rôle prédictif du polymorphisme fonctionnel 5-HTTLPR sur la réponse au traitement par l’escitalopram des patients souffrant d’un trouble obsessionnel compulsif
    Medical condition: obsessive compulsive disorder
    Disease: Version SOC Term Classification Code Term Level
    12.0 10029898 Obsessive-compulsive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003080-38 Sponsor Protocol Number: GOAT_1-2_1407 Start Date*: 2015-06-26
    Sponsor Name: Radboud University Nijmegen Medical Centre, Donders Institute for Brain, Cognition and Behaviour
    Full Title: Glutamatergic medication in the treatment of Obsessive Compulsive Disorder (OCD) and Autism Spectrum Disorder (ASD)
    Medical condition: - Obsessive-compulsive disorder - Autistic Diorder, Aspergers' Disorder, PDD NOS
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-000256-33 Sponsor Protocol Number: Ra-P-OCD-01 Start Date*: 2019-06-27
    Sponsor Name:Uppsala University Hospital
    Full Title: A randomized, double-blinded, placebo-controlled study of Rituximab in patients with Psychosis and/or Obsessive Compulsive Disorder, with an indication of immune system involvement
    Medical condition: Obsessive-compulsive disorder (OCD) or Obsessive-compulsive behaviour (OCB) or psychotic disorder (PD) in which there is an indication of immune system involvement.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10029898 Obsessive-compulsive disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022914-15 Sponsor Protocol Number: A3051123 Start Date*: 2012-03-01
    Sponsor Name:Pfizer, S.L.U.
    Full Title: A PHASE 4, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO -CONTROLLED, MULTICENTER STUDY EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF 12 WEEKS VARENICLINE TARTRATE 1MG BID AND BUPROPION HYD...
    Medical condition: Nicotine Addiction with the desire to quit smoking
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10053325 Smoking cessation therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) DK (Completed) FI (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 07:38:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA